


Burkina Faso ALMA Quarterly Report Quarter Two, 2026



Scorecard for Accountability and Action



Malaria is present throughout Burkina Faso, with transmission most intense in the southern part of the country. The annual reported number of malaria cases in 2024 was 11,111,584 with 3,734 deaths.

Metrics

Policy

Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Zero Malaria Starts With Me Launched		
End Malaria Council and Fund Launched		

Resistance Monitoring, Implementation and Impact

Drug efficacy studies conducted since 2019 and data reported to WHO		
Insecticide resistance monitored since 2020 and data reported to WHO		
% of vector control in the last year with next generation materials		81
ACTs in stock (>6 months stock)		
RDTs in stock (>6 months stock)		
On track to reduce malaria incidence by at least 75% by 2025 (vs 2015)		
On track to reduce malaria mortality by at least 75% by 2025 (vs 2015)		

Tracer Indicators for Maternal and Child Health and NTDs

Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2024)		65
% of Neglected Tropical Disease MDAs Achieving WHO Targets		80
National Budget Allocated to NTDs		
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2025)	▲	42
DPT3 coverage 2025 (vaccination among 0-11 month olds)		91
Climate Change and VBDs in NDCs		

Key

	Target achieved or on track
	Progress but more effort required
	Not on track
	No data
	Not applicable

Malaria - The Big Push towards 2030

Africa is at the centre of a perfect storm that threatens to disrupt malaria services and undo decades of progress. Countries must act urgently to both prevent and mitigate the adverse effects of the ongoing global financial crisis, decreasing ODA, increasing biological threats, climate change, and humanitarian crises. These threats represent the most serious emergency facing malaria in 20 years and will lead to malaria upsurges and epidemics if not addressed. To get back on track and eliminate malaria, US\$5.2 billion is needed annually to fully finance country national malaria plans, and urgently fill gaps created by the recent reductions in ODA. Extreme weather events and climate change present a significant threat. By the 2030s, 150 million additional people will be at risk of malaria because of warmer temperatures and increased rainfall. Countries must also take action to confront the threats of insecticide and drug resistance, reduced efficacy of rapid diagnostic tests, and the invasive *Anopheles stephensi* mosquito which spreads malaria in both urban and rural areas. The malaria toolkit continues to expand. WHO has approved the use of dual-insecticide mosquito nets that are 43% more effective than traditional mosquito nets and will address the impact of insecticide-resistance. WHO have also recently approved the use of Spatial Repellents. New medicines for treating malaria and two malaria vaccines for children have also been approved with an increasing number of countries deploying these new tools. Malaria can serve as a pathfinder for primary health care strengthening, climate change and health, and Universal Health Coverage. Countries must work to sustain and increase domestic resource commitments including through multisectoral End Malaria and NTD Councils and Funds, which have raised over US\$245 million to date.

A recent report by ALMA and MNM UK, “The Price of Retreat,” highlights the expected impact of malaria between 2025-2030 on GDP, trade and key sectors for development in Africa. If Burkina Faso cannot sustain malaria prevention due to reductions in malaria financing, this would lead to an estimated 32,405,024 additional cases, 62,498 more deaths, and GDP loss of US\$1.3 billion between 2025 and 2030. However, if we mobilise the necessary resources and achieve a 90% reduction in malaria, in Burkina Faso there will be a US\$2.6 billion increase in GDP.

Progress

Burkina Faso has carried out insecticide resistance monitoring and has reported the results to WHO, and in response to these results, the majority of the vector control commodities used in the country are next generation insecticides and nets. The country has also carried out drug resistance testing since 2018 and has reported the results to WHO. The national strategic plan includes activities targeting refugees. Burkina Faso has launched Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, President Advocate Duma Gideon Bokoaló, Burkina Faso has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Scorecard and this has been updated regularly and is shared on the ALMA scorecard hub. The country is congratulated for the launch of the End Malaria Council. The country has launched its national youth corps. The Honourable Minister of Health has been appointed as an ALMA RBM Malaria champion.

Impact

The annual reported number of malaria cases in 2024 was 11,111,584 with 3,734 deaths.

Key Challenges

- Insecticide resistance threatens vector control effectiveness.

- Serious funding gaps to sustain essential life-saving malaria services including the impact of recent reductions in ODA

Previous Key Recommended Action

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Work to ensure that malaria elimination is prioritised in the America First Global Health Strategy Country Memorandum of Understanding, and that costed prioritised plans are developed	Q1 2026		The US funding agreement was signed. The total funding from 2026 to 2030 is \$47,710,000. The investment areas for this funding are SMC, IPTp, RDTs, LLINs, Artesunate. The orders for SMC drugs for 19 districts for 2027 covered by the US funding have been placed.

Reproductive, Maternal, Newborn, Adolescent and Child Health

Progress

Burkina Faso has made good progress in the tracer RMNCAH intervention DPT3. Burkina Faso has significantly enhanced the tracking and accountability mechanisms with the development of the Maternal, Newborn, Child and Adolescent Health Scorecard.

Previous Key Recommended Action

The country has responded positively to the RMNCAH recommended actions addressing low coverage of ART coverage in children, with a 2% increase in coverage reported in the last year.

Neglected Tropical Diseases

Progress

Progress in addressing Neglected Tropical Diseases (NTDs) in Burkina Faso is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis and schistosomiasis. Preventive chemotherapy coverage in Burkina Faso is 100% for trachoma and for Soil Transmitted Helminthiasis (100%) as the two diseases are under surveillance only. It is also very low for lymphatic Filariasis (15%), very good for onchocerciasis (79%) and for schistosomiasis (97%). Overall, the NTD preventive chemotherapy coverage index for Burkina Faso in 2024 is 65. Apart from low MDA coverage for Lymphatic Filariasis, the country reached WHO targets for the other MDAs. The country has recently included Vector-Borne Disease in the Nationally Determined Contribution.

Key

	Action achieved
	Some progress
	No progress
	Deliverable not yet due